AtriCure, Inc. (ATRC) Stock

AtriCure, Inc. (ATRC) is a Healthcare stock trading at $28.84 (as of 2026-06-18), with a market capitalization of $1.33B and a trailing P/E of -287.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

AtriCure, Inc. develops and sells surgical treatment systems and related disposable devices for cardiac tissue ablation and procedures involving intercostal nerves. Its product lines include radiofrequency ablation clamps and pens, cryoablation and guided coagulation systems, and implantable or surgical adjunct devices, which it supplies to medical centers in the United States and internationally.

Valuation — source: SEC EDGAR (first-party)
Price	$28.84
Market Cap	$1.33B
P/E Ratio	-287.9
EV / EBITDA	151.9
Price / Book	2.97
Price / Sales	2.64
DCF Value (model)	$18.62
DCF Upside vs Price	-35.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$534.53M
Net Margin	-2.1%
Return on Equity	-0.9%
Debt / Equity	0.12
Current Ratio	4.29
Revenue Growth (YoY)	14.3%
EPS Growth (YoY)	-100.0%
FCF Growth (YoY)	-40.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	5.64 (safe)
Piotroski F-Score	7/9 (strong)

Valuation vs Sector & Industry
Stock P/E	-287.9
Sector P/E (Healthcare)	21.0
Industry P/E (Medical Equipment)	31.7
vs Sector	-1473.6%
vs Industry	-1007.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($193.99M)
Institutional Holders Tracked	10
Congressional Trades (recent)	4

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Michael H. Carrel
Employees	1,300
Country	US
IPO Date	2005-08-05

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.